<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515225</url>
  </required_header>
  <id_info>
    <org_study_id>7947</org_study_id>
    <nct_id>NCT04515225</nct_id>
  </id_info>
  <brief_title>COVID-19 Prevalence in HIV-infected Patients</brief_title>
  <acronym>SeCoVIHA</acronym>
  <official_title>Seroprevalence of SARS-CoV-2 Antibodies Among Adult Patients Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      North-east area of France was hit in February 2020 by the new coronavirus disease, more
      severely than other French regions. Factors affecting the evolution of the disease and its
      severity have been quickly identified, among them figuring different kinds of immune
      deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those
      patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of
      severe COVID infection. In this context, the primary objective of our study is aimed at
      evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients
      followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the
      antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors
      with the presence of antibodies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence of SARS-CoV-2</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>SARS-CoV-2 antibodies will be detected with a rapid test detecting IgG and IgM, at inclusion, and during a 6-month and a 12-month visit, in order to assess the prevalence of the virus in this population.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV-infected patients</arm_group_label>
    <description>All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>Blood Sample</description>
    <arm_group_label>HIV-infected patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients on follow-up in a single University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults (&gt; 18 years)

          -  HIV-infected patients

          -  subjects with social insurance

          -  subjects able to understand study purposes, and to give a written and informed consent

        Exclusion Criteria :

          -  subjects unable to understand informations on the study, and to provide informed
             consent

          -  subjects under guardianship or curatorship

          -  subjects under judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-infection</keyword>
  <keyword>AIDS</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>CD4 cell count</keyword>
  <keyword>plasma HIV</keyword>
  <keyword>RNA</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

